

AMENDMENTS TO THE CLAIMS

Listing of Claims:

This listing of claims is to replace all previous listings.

1-29. Cancelled

30. (Currently Amended) A composition for controlling viability of [[a]] an explanted tissue or organ including:

a potassium channel opener or adenosine receptor agonist;

~~a compound for inducing local anaesthesia~~ anesthetic; and

~~a compound for inhibiting transport of sodium and hydrogen ions across a plasma membrane of a cell in the tissue~~ a sodium hydrogen exchange inhibitor.

31. (Currently Amended) A composition according to claim 30 wherein the ~~compound for inhibiting transport of sodium and hydrogen ions~~ sodium hydrogen exchange inhibitor is selected from the group consisting of: ~~N-amidino-3,5-diamino-6-chloropyrzhine-2-carboximide hydrochloride dehydrate~~ amiloride, EIPA, cariporide (HOE—642), eniporide, ~~Triamterene~~ triamterene, EMD 84021, EMD 94309, EMD 96785, EMD 85131, HOE 694, ~~B11-B-513~~ BII B-513 and T-162559

32. (Currently Amended) A composition according to claim 30 wherein the sodium hydrogen exchange inhibitor ~~compound~~ is ~~N-amidino-3,5-diamino-6-chloropyrzhine-2-carboximide hydrochloride dehydrate~~ amiloride.

33. (Original) A composition according to claim 30 wherein the concentration of the compound is between about 1nM to 1mM.

34. (Currently Amended) A composition according to claim 30 wherein the composition further includes at least one compound selected from the group consisting of:

a compound for reducing the uptake of water by a cell in the tissue;

diazoxide;

a source of magnesium ~~in an amount for increasing the amount of magnesium in a cell~~
~~in the tissue~~ in a concentration of between about 0.5mM to about 20mM; and

a source of calcium ~~in an amount for decreasing the amount of calcium within a cell in~~
~~the tissue~~ in a concentration of between about 0.1mM to about 2.5mM.

Claims 35-49 (Cancelled).

50. (New) A composition for controlling viability of an explanted tissue or organ including:

a first compound comprising a potassium channel opener or adenosine receptor agonist;

a second compound comprising a local anaesthetic; and

a third compound comprising a sodium hydrogen exchange inhibitor, wherein each of the three compounds is different.

51. (New) A composition according to claim 50, wherein the sodium hydrogen exchange inhibitor is selected from the group consisting of amiloride, EIPA, cariporide, eniporide, triamterene, EMD 84021, EMD 94309, EMD 96785, EMD 85131, HOE 694, BII B-513 and T-162559.

52. (New) A composition according to claim 50, wherein the sodium hydrogen exchange inhibitor is amiloride.

53. (New) A composition according to claim 50, wherein the concentration of the compound is between about 1nM to 1mM.

54. (New) A composition according to claim 50, wherein the composition further includes at least one compound selected from the group consisting of:

a compound for reducing the uptake of water by a cell in the tissue;

diazoxide;

a source of magnesium in a concentration of between about 0.5mM to about 20mM;

and

a source of calcium in a concentration of between about 0.1mM to about 2.5mM.

AMENDMENTS TO THE SPECIFICATION

The Examiner has noted that the term "chloropyrazine" was misspelled in the specification. Applicants submit the following amendments to correct this typographical error as well as other typographical errors that Applicants have noticed. No new matter is believed to be added by these changes.

Further to the Examiner's request, please replace paragraph [0052], which corresponds to the passage the Examiner references on page 10, with the following paragraph which has been marked up to show the change in line two below:

[0052] Preferably, the sodium hydrogen exchange inhibitor is Amiloride (N-amidino-3,5-diamino-6-chloropyrazine-2-carboximide hydrochloride dihydrate). Amiloride inhibits the sodium proton exchanger (Na^+/H^+ exchanger also often abbreviated NHE-1) and reduces calcium entering the cell. During ischemia excess cell protons (or hydrogen ions) are believed to be exchanged for sodium via the Na^+/H^+ exchanger.

Please replace paragraph [0051] with the following paragraph which has been marked up to show the changes in the sixth line below:

[0051] Preferably the compound for inhibiting transport of sodium and hydrogen across the membrane of the cell in the tissue may be selected from one or more of the group consisting of Amiloride, EIPA(5-(N-entyl-N-isopropyl)-amiloride), cariporide (HOE-642), eniporide, Triamterene (2,4,7-triamino-6-phenylteride), EMD 84021, EMD 94309, EMD 96785, EMD 85131, HOE 694[[.]], ~~B-11-B-513~~ BII B-513, and T-162559 are other inhibitors of the isoform 1 of the Na^+/H^+ exchanger.

Please replace paragraph [0073] with the following paragraph which has been marked up to show the deletion of a "9" which inadvertently precedes the word "Apnea" in line ten below:

[0073] Suitable adenosine receptor agonists may be selected from: N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (NECA), 2-[p-(2-carboxyethyl)phenethyl-amino-5'-N-ethylcarboxamido adenosine (CGS-21680), 2-chloroadenosine, N.sup.6-[2-(3,5-demethoxyphenyl)-2-(2-methoxyphenyl)ethyladenosine, 2-chloro-N.sup.6-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-ribofuranosyl]-adenine (AB-MECA), ([1S-[1 a,2b,3b,4a(S*)]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-1-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-yl]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexyladenosine (CHA). Others include full adenosine A1 receptor agonists such as N-[3-(R)-tetrahydrofuranyl]-6-aminopurine riboside (CVT-510), or partial agonists such as CVT-2759 and allosteric enhancers such as PD81723. Other agonists may include N6-cyclopentyl-2-(3-phenylaminocarbonyltriazene-1-yl-) adenosine (TCPA), a very selective agonist with high affinity for the human adenosine A1 receptor and allosteric enhancers of A1 adenosine receptor includes the 2-amino-3-naphthylthiophenes.